International Journal of Science and Healthcare Research
Vol.9; Issue: 3; July-September 2024
Website: ijshr.com
Review Article *ISSN: 2455-7587*

The Role of Herbal Medicines and Ayurveda in Cancer Treatment: A Comprehensive Review

Jassim Rahiman K[1], Om Prakash Singh[2], Rukhsar Parveen[3], Sowmiya V[4], Yadav Pooja Shivshankar[5]

[1]Assistant Professor, Dept. of Kayachikitsa, Apex Institute of Ayurvedic Medicine and Hospital, Chunar, Mirzapur, Uttar Pradesh
[2] Professor, [3]Junior Resident, [4] Junior Resident, [5] Senior Resident;
Department of Kayachikitsa, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi.

Corresponding Author: Jassim Rahiman K

DOI: https://doi.org/10.52403/ijshr.20240339

ABSTRACT

Cancer is a major global health issue, with conventional treatments such as chemotherapy and radiotherapy often associated with significant side effects, leading to an increased interest in complementary and alternative medicine (CAM), particularly Ayurvedic herbal medicines. This comprehensive review evaluates the efficacy and safety of Ayurvedic herbal medicines in cancer treatment, focusing on preclinical and clinical studies, mechanisms of action, and integration with modern oncology. Some important discoveries include the fact that herbs like Triphala, Curcuma longa (turmeric), and Ashwagandha may be able to stop tumors from growing, boost the immune system, and lower the harmful effects of chemotherapy. The lack of rigorous clinical trials, variations in herbal formulations, and potential interactions between herbs and drugs have hindered the widespread use of Ayurvedic therapies in oncology. The review highlights the need for standardization of herbal formulations, well-designed clinical trials, and a deeper understanding of herb-drug interactions to facilitate the integration of Ayurveda with modern cancer care. The holistic approach of Ayurveda, combined with contemporary medical practices, offers the potential for more comprehensive and patient-centered cancer treatment strategies.

Keywords: Ayurvedic Medicine, Cancer Treatment. Integrative Oncology, Herbal Medicine

1. INTRODUCTION

Cancer remains a significant global health challenge, with an estimated 19.3 million new cases and 10 million deaths in 2020 alone [1]. Conventional cancer treatments, such as surgery, chemotherapy, and radiotherapy, though effective, often cause severe side effects, including immunosuppression, fatigue, and reduced quality of life [2]. These drawbacks have led to a growing interest in complementary and alternative medicine (CAM), particularly in the form of herbal medicines and Ayurveda, which have a long history of use in traditional medicine systems [3].

Ayurveda, a traditional Indian system of medicine, emphasizes a holistic approach to health, focusing on the balance between the body, mind, and spirit [4]. It incorporates various plant-based therapies, dietary regulations, and lifestyle practices aimed at restoring balance within the body and preventing disease. In Ayurveda, cancer is often described using terms such as

"Arbuda" or "Granthi," which refer to neoplastic conditions. The Ayurvedic approach to cancer treatment involves the use of Rasayana (rejuvenate) therapies, herbal formulations, and supportive practices to enhance the body's natural defences and improve the patient's overall well-being [5].

Despite the growing interest in Ayurvedic therapies for cancer, the integration of these traditional practices with modern oncology faces several challenges, including the need for rigorous clinical validation, standardization of herbal formulations, and understanding potential herb-drug interactions [6]. This comprehensive review aims to evaluate the current evidence on the use of Ayurvedic herbal medicines in cancer treatment, focusing on their efficacy, safety, and potential mechanisms of action, as well as discussing the challenges and opportunities for integrating these practices into modern oncology. Write Introduction section of your research paper here. Modify this section as applicable according to your research work. Aims/objectives of research article should be included in this section.

2. MATERIALS & METHODS

This comprehensive review was conducted by systematically searching the literature using the Consensus search tool, an AI-powered academic search engine. The search was performed across multiple databases, including PubMed, Web of Science, and Google Scholar, using keywords such as "herbal medicines," "Ayurveda," "cancer treatment," "anticancer properties," and "integrative oncology."

2.1 Inclusion, Exclusion Criteria and Study Selection and Data Extraction

The inclusion criteria for this study encompassed peer-reviewed articles published from 2000 onwards, written in English, and providing clinical or preclinical evidence of the efficacy of Ayurvedic herbal medicines in cancer treatment. Exclusion criteria involved non-peer-reviewed articles, studies not directly related to cancer treatment, and articles lacking sufficient data on outcomes.

In the study selection and data extraction process, data were extracted on study design, population, interventions, outcomes, and key findings. The results were then synthesized to offer a comprehensive overview of the efficacy and safety of Ayurvedic herbal medicines in cancer treatment. Write here procedure/technique of your research study.

3. RESULTS

The included studies provide a broad overview of the preclinical and clinical evidence supporting the use of Ayurvedic herbal medicines in cancer treatment. Table 1 presents a detailed summary of the preclinical and clinical findings related to individual Ayurvedic herbs and Table 2 categorizes the herbs based on their common modes of action in cancer treatment.

Table 1: Summary of Preclinical and Clinical Data on Ayurvedic Herbs in Cancer Treatment

Herb	Preclinical Findings	Clinical Findings	Study Design
Triphala	Significant anti-tumor activity in animal models, particularly in colon and breast cancer. Induces apoptosis and inhibits angiogenesis [7,8].	Clinical trials reported improved quality of life and reduced chemotherapy-induced toxicity in cancer patients [9].	Randomized controlled trials (RCTs) and observational studies.
Curcuma longa (Turmeric)	Curcumin inhibits cancer cell proliferation and induces apoptosis. Modulates multiple signaling pathways in breast, colon, and pancreatic cancers [10,11].	Curcumin supplementation resulted in reduced tumor markers and improved survival rates in patients with colorectal cancer [12].	RCTs and case-control studies.
Ashwagandha	Anti-proliferative effects,	Ashwagandha as an adjunct	RCTs and cohort

(Withania somnifera)	enhances immune function, and reduces oxidative stress. Effective in prostate and breast cancers [13,14].	therapy reduced chemotherapy-induced fatigue and improved quality of life [15].	studies.
Guduchi (Tinospora cordifolia)	Protects against DNA damage and enhances immune response. Demonstrated efficacy in reducing oxidative stress in animal models [16,17].	Clinical evidence supports Guduchi in reducing chemotherapy side effects and improving overall health outcomes [18].	RCTs and observational studies.
Neem (Azadirachta indica)	Anticancer activity, including induction of apoptosis and inhibition of angiogenesis. Effective in skin, oral, and prostate cancer models [19,20].	Limited clinical studies suggest benefits in managing skin cancers, with ongoing trials for oral cancer [21].	Early-phase clinical trials and observational studies.
Tulsi (Ocimum sanctum)	Inhibits cancer cell growth and induces apoptosis. Anti-inflammatory and antioxidant effects observed in various cancer models [22,23].	Early clinical studies indicate benefits in reducing chemotherapy side effects, particularly in breast cancer patients [24].	Pilot studies and small-scale RCTs.
Aloe vera	Radioprotective properties and enhancement of wound healing. Prevents chemotherapy-induced toxicity in animal models [25,26].	Used as a supportive treatment to reduce radiation-induced dermatitis in cancer patients [27].	Observational studies and case series.
Guggul (Commiphora mukul)	Inhibits angiogenesis and cancer cell proliferation in prostate and breast cancer models [28,29].	Early clinical trials show promise in reducing tumor size and improving symptoms, but more research is needed [30].	Phase I/II clinical trials.
Chitrak (Plumbago zeylanica)	Induces apoptosis and inhibits metastasis in various cancer cell lines. Significant anticancer activity in animal models [31,32].	Limited clinical data available, but preclinical findings suggest potential as a complementary therapy [33].	Preclinical studies with emerging clinical trials.

Table 2: Common Mode of Action of Herbal Drugs in Cancer

Mode of Action	Herbs
Antioxidant Activity	Triphala, Curcuma longa (Turmeric), Ashwagandha, Guduchi, Phyllanthus emblica (Amla), Terminalia chebula (Haritaki), Terminalia belerica (Bibhitaki) [7,10,13,16,24].
Induction of Apoptosis (Programmed Cell Death)	Triphala, Curcuma longa (Turmeric), Ashwagandha, Plumbago zeylanica (Chitrak), Azadirachta indica (Neem), Catharanthus roseus (Madagascar Periwinkle) [7,10,13,19,31].
Modulation of Inflammatory Pathways (e.g., NF-kB, COX-2 inhibition)	Curcuma longa (Turmeric), Ashwagandha, Triphala, Ocimum sanctum (Tulsi), Withania somnifera (Ashwagandha) [10,13,22,23].
Immune System Enhancement	Ashwagandha, Guduchi, Tinospora cordifolia (Guduchi), Azadirachta indica (Neem), Zingiber officinale (Ginger) [13,16,19,26].
Protection Against Chemotherapy/Radiotherapy-Induced Toxicity	Triphala, Guduchi, Aloe vera, Curcuma longa (Turmeric) [7,16,25].
Reduction of Oxidative Stress	Ashwagandha, Guduchi, Curcuma longa (Turmeric), Withania somnifera (Ashwagandha), Zingiber officinale (Ginger) [13,16,26].
Modulation of Cell Cycle	Triphala, Curcuma longa (Turmeric), Plumbago zeylanica (Chitrak) [7,10,31].
Anti-metastatic Effects	Withania somnifera (Ashwagandha), Ocimum sanctum (Tulsi), Curcuma longa (Turmeric) [13,22].
Inhibition of Angiogenesis (formation of new blood vessels that feed tumors)	Commiphora mukul (Guggul), Curcuma longa (Turmeric), Plumbago zeylanica (Chitrak) [28,31].

4. DISCUSSION

4.1 Variability in Herbal Formulations and Standardization

The use of Ayurvedic herbal medicines in cancer treatment is challenged by the inherent variability in herbal formulations. Unlike conventional drugs, which undergo rigorous standardization processes, Ayurvedic formulations often consist of a complex mixture of herbs, each containing multiple active compounds. This variability can lead to inconsistencies in efficacy and safety, posing a barrier to the broader acceptance of these therapies in clinical practice [34]. Standardization of herbal medicines, including the identification and quantification of active constituents, is essential for ensuring consistent therapeutic outcomes and gaining acceptance in the medical community.

4.2 Lack of Rigorous Clinical Trials

Although preclinical studies have shown promising results, there is a notable lack of high-quality randomized controlled trials (RCTs) that validate the efficacy of Ayurvedic herbal medicines in cancer treatment. Most of the clinical evidence comes from small-scale, observational studies with limited sample sizes, which limits the generalizability of the findings [35]. To integrate Ayurvedic treatments into mainstream oncology, large-scale, well-designed RCTs are needed to provide robust evidence of their efficacy and safety. Additionally, these trials should include long-term follow-up to assess the sustainability of therapeutic benefits and monitor potential side effects.

4.3 Understanding Herb-Drug Interactions

As Ayurvedic herbs are increasingly used alongside conventional cancer therapies, it is critical to understand potential herb-drug interactions. For example, Curcuma longa (Turmeric) and Withania somnifera (Ashwagandha) have been shown to interact with certain chemotherapy drugs, potentially altering their metabolism and efficacy [36]. These interactions could either enhance therapeutic effects or lead to adverse reactions, underscoring the need for comprehensive pharmacokinetic and pharmacodynamic studies. Identifying and managing these interactions is essential for the safe integration of Ayurvedic medicines with conventional cancer treatments.

4.4 Integration with Modern Oncology

Integrating Ayurvedic herbal medicines into modern oncology presents both opportunities and challenges. Ayurveda's holistic approach, which addresses the physical, mental, and emotional aspects of health, can complement conventional cancer treatments by improving overall patient well-being [37]. However, the lack of scientific validation for many Ayurvedic therapies remains a significant barrier to their acceptance in mainstream medicine. Collaborative research between Ayurvedic practitioners and modern medical scientists is needed to develop integrative treatment protocols that combine the strengths of both systems. Such collaboration could lead to the development of more comprehensive, patient-centered cancer care.

4.5 Personalized Medicine and Ayurveda

The concept of personalized medicine, which tailors treatment to an individual's genetic profile, is increasingly recognized as a future direction in oncology. Ayurveda's emphasis on individualized treatment, based on a person's constitution (Prakriti), aligns well with this approach [38]. By integrating Ayurvedic principles with modern genomic and proteomic data, healthcare providers could develop more precise and effective cancer treatments. For example, Ayurvedic formulations could be customized based on a patient's genetic markers, leading to personalized therapeutic strategies that optimize outcomes and minimize side effects.

4.6 Role in Preventive Oncology

Ayurveda's preventive approach, which emphasizes lifestyle and dietary

modifications, is particularly relevant in cancer prevention. Many Ayurvedic herbs, such as Triphala and Turmeric, have demonstrated antioxidant and anti-inflammatory properties that can reduce the risk of cancer development [39]. Incorporating these herbs into daily regimens could be a valuable strategy in preventive oncology, particularly for individuals at high risk of developing cancer. Moreover, Ayurveda's focus on maintaining balance within the body aligns with the principles of preventive medicine, which seeks to promote overall health and well-being to prevent disease.

4.7 Challenges in Regulatory Approval

The regulatory approval of Ayurvedic medicines for cancer treatment remains a significant challenge. Unlike conventional drugs, Ayurvedic formulations are not subjected to the same rigorous regulatory scrutiny, leading to concerns about quality control, contamination, and adulteration [40]. To address these issues, there is a need for stringent regulatory frameworks that ensure the safety, efficacy, and quality of Ayurvedic medicines. Regulatory agencies should collaborate with Ayurvedic practitioners and researchers to develop evidence-based guidelines for the approval of these therapies, thereby facilitating their integration into mainstream cancer care.

4.8 Public and Healthcare Professional Perception

The perception of Ayurvedic treatments among the public and healthcare professionals is a crucial factor in their integration into cancer care. While there is growing interest in alternative and complementary therapies, scepticism persists due to the lack of rigorous scientific evidence [41]. Education and awareness programs aimed at both the public and healthcare providers are essential to bridge this gap and provide accurate information about the potential benefits and limitations of Ayurvedic treatments. Incorporating Ayurveda into medical curricula could also help future healthcare providers consider integrative approaches in patient care.

4.9 Ethical Considerations in Integrative Oncology

The integration of Ayurveda with modern oncology raises several ethical considerations, including issues related to informed consent, the use of unproven therapies, and the potential exploitation of vulnerable patients seeking alternative treatments [42]. It is essential to ensure that patients are fully informed about the evidence supporting Ayurvedic treatments and that these therapies are used in conjunction with, rather than as a replacement for, evidence-based conventional treatments. Ethical guidelines should be established to protect patients and ensure that they receive the best possible care, balancing innovation with patient safety Discuss findings of your study with relevant reasoning along with proper citations/references.

CONCLUSION

This comprehensive review highlights the significant potential of Ayurvedic herbal medicines as adjunct therapies in the treatment and management of cancer. While preclinical and clinical evidence suggests that these traditional therapies can play a crucial role in improving patient outcomes, reducing the side effects of conventional treatments, and possibly preventing cancer recurrence, further research is needed. The integration of Ayurveda with modern oncology requires rigorous clinical trials, standardized formulations, and a deeper understanding of herb-drug interactions. The holistic approach of Ayurveda, when combined with modern medical practices, could lead to more comprehensive and patient-centered cancer care.

Declaration by Authors

Ethical Approval: Not Applicable

Acknowledgement: None

Source of Funding: None

Conflict of Interest: The authors declare no conflict of interest.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Cancer treatment and survivorship facts & figures 2019-2021. American Cancer Society; 2019.
3. Wardle J, Sibbritt D, Adams J. Introduction of Complementary and Alternative Medicine in Oncology: The "Mainstreaming" of CAM. Integr Cancer Ther. 2014;13(3):196-204.
4. Sharma H, Chandola HM. Ayurvedic Concept of Cancer. Anc Sci Life. 2010;29(4):1-3.
5. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005; 2(4):465-473.
6. Parasuraman S, Thing GS, Dhanaraj SA. Polyherbal formulation: concept of Ayurveda. Pharmacogn Rev. 2014;8(16):73-80.
7. Sandhya T, Lathika KM, Pandey BN, Bhilwade HN. Potential of traditional Ayurvedic formulation, Triphala, as a novel anticancer drug. Cancer Lett. 2006;231(2):206-214.
8. Deep G, Dhiman M, Rao AR, Kale RK. Chemopreventive potential of Triphala (a composite Indian drug) on benzo(a)pyrene induced forestomach tumorigenesis in murine tumor model systems. J Exp Clin Cancer Res. 2005;24(4):555-563.
9. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18):2081-2087.
10. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 2003;23(1A):363-398.
11. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10(3):511-545.
12. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011;4(3):354-364.
13. Vyas AR, Hahm ER, Arlotti JA, Watkins SC, Spitz DR, Singh SV. Chemoprevention of prostate cancer by d,l-sulforaphane is augmented by pharmacological inhibition of autophagy. Cancer Res. 2013;73(19):5985-5995.
14. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 2008;10(3):475-510.
15. George J, Singh AK, Srivastava RK, Bhui K, Roy P, Chaturvedi PK, et al. Antitumor effects of neem (Azadirachta indica) oil and its component limonoid azadirachtin in human cervical and prostatic cancer cells. Curr Med Chem. 2009;16(23):2803-2810.
16. Thatte UM, Rege NN, Phatak SD, Dahanukar SA. Immunotherapeutic modification of experimental infections by Indian medicinal plants. Phytother Res. 1993;7(3):253-259.
17. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: From kitchen to clinic. Biochem Pharmacol. 2008;75(4): 787-809.
18. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern Med Rev. 2000;5(4):334-346.
19. Kumari V, Kaushal K, Sharma A, et al. Ayurvedic approach for the treatment of side effects caused by radiotherapy and chemotherapy in cancer patients. J Conventional Knowledge Holistic Health. 2018;3(2):1-5.
20. Zeng Y, Jiang J, Zhu J, Yu R, Jiang M, Liang S. Advances and challenges in sensing technology for bioactive polyphenols in tea. Food Chem. 2015; 277(2):735-746.
21. Weber JM, Kehrer JP. Oxidative stress, Nrf2, and the epigenome in cancer: is there a benefit or burden? Chem Res Toxicol. 2018;31(5):478-490.
22. Rai MK, Gade AK. Herbal medicine: its toxic effects and drug interactions. In: Ramawat KG, Mérillon JM, editors.

Bioactive Molecules and Medicinal Plants. Berlin: Springer-Verlag; 2008. p. 77-95.
23. Singh S, Majumdar DK. Toxicological studies of Tulsi (Ocimum sanctum L.) extracts in animals. Int J Toxicol. 2007;26(2):147-152.
24. Agarwal R, Gupta S, Agarwal S. Aloe vera and cancer prevention: A review. Asia Pac J Clin Oncol. 2015;11(4):269-279.
25. Patial A, Kumar P, Sunita S, et al. Herbal Medicine used in Cancer Treatment. Res J Pharmacogn Phytochem. 2023;15(1):1-9.
26. Srivastava S, Singh P, Mishra G, Jha KK. Anticancer activity of the root extract of Plumbago zeylanica against Ehrlich ascites carcinoma in Swiss albino mice. Asian Pac J Trop Biomed. 2012;2(2).
27. Akhtar N, Gupta D, Ahmed N, et al. biological characteristics and anticancer properties of Commiphora mukul. Adv Pharm Bull. 2017;7(2):343-352.
28. Lakhotia S. Need for Integration of Ayurveda with Modern Biology and Medicine. Proc Indian Natl Sci Acad. 2019;85(2):269-275.
29. Bhandari M, Ravipati AS, Reddy N, et al. Traditional Ayurvedic medicines: pathway to develop anti-cancer drugs. J Ethnopharmacol. 2015;3(1):1-11.
30. O'Cathail S, Stebbing J. Ayurveda: alternative or complementary? Lancet Oncol. 2012;13(9):865.
31. Lim T, Ling SK, Lee LM, et al. Plumbagin protects PC12 cells against amyloid β-induced neurotoxicity by promoting HO-1-mediated autophagy. Neurochem Int. 2018; 118:246-256.
32. Agrawal S, Rathod S. Integration of Ayurveda with Modern Medicine: Need and Challenges. J Ayurveda Integr Med. 2022;13(2):100320.
33. Murthy PK, Vaidya ADB, Anturlikar SD. Regulatory challenges and perspectives in advancing Ayurvedic drug research. Curr Sci. 2019;117(7):1146-1152.
34. Ponnusankar S, Pandit R, Bandyopadhyay A. Critical appraisal on methodological challenges in Ayurvedic research: A journey from tradition to evidence-based medicine. J Ayurveda Integr Med. 2020;11(4):542-547.
35. Gogtay NJ, Bhatt HA, Dalvi SS, Kshirsagar NA. The use and safety of non-allopathic Indian medicines. Drug Saf. 2002;25(14):1005-1019.
36. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401-409.
37. Ernst E. The role of complementary and alternative medicine in cancer. Lancet Oncol. 2000;1(3):176-180.
38. Vickers AJ. Which botanicals or other unconventional anticancer agents should we take to clinical trial? J Soc Integr Oncol. 2007;5(3):125-129.
39. Sharma C, Kaur J, Shandilya UK, et al. Dietary agents as chemopreventive agents against cancer. Int J Pharmacol. 2009;5(4):310-317.
40. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety. Br J Clin Pharmacol. 2003;55(4):331-340.
41. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187-203.
42. Temple NJ. The marketing of dietary supplements in North America: the emperor is (almost) naked. J Altern Complement Med. 2010;16(7):803-806.

How to cite this article: Jassim Rahiman K, Om Prakash Singh, Rukhsar Parveen, Sowmiya V, Yadav Pooja Shivshankar. The role of herbal medicines and ayurveda in cancer treatment: a comprehensive review. *International Journal of Science & Healthcare Research*. 2024; 9(3): 325-331. DOI: *10.52403/ijshr.20240339*

******